BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Ensem Therapeutics, Inc announced that its partner BeiGene has dosed the first five patients in its first-in-human phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of solid tumours. The achievement triggers a milestone payment from BeiGene, which licensed the compound (formerly ETX-197) from Ensem in November 2023. BG-68501 is the first clinical stage compound to emerge from Ensem’s Kinetic Ensemble platform, a suite of novel AI/ML, computational and experimental technologies to uncover cryptic pockets in target proteins for drug discovery.
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Study to evaluate the effects of Bria-OTS„ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER,...
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
Glenmark Pharmaceuticals on Tuesday said its unit has inked a marketing and distribution agreement with BeiGene to commercialise the latter's oncology medicines, Tislelizumab and Zanubrutinib in India.
Less than a year after the end of a PD-1 deal with Novartis, BeiGene is looking at new partnerships that could bring in new assets it could develop or commercialize, or out-license some of its substantial cancer pipeline.
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024